JP5583117B2 - 非小細胞肺癌およびアジュバント化学療法に関する予後診断的および予測的な遺伝子シグネチャー - Google Patents

非小細胞肺癌およびアジュバント化学療法に関する予後診断的および予測的な遺伝子シグネチャー Download PDF

Info

Publication number
JP5583117B2
JP5583117B2 JP2011508777A JP2011508777A JP5583117B2 JP 5583117 B2 JP5583117 B2 JP 5583117B2 JP 2011508777 A JP2011508777 A JP 2011508777A JP 2011508777 A JP2011508777 A JP 2011508777A JP 5583117 B2 JP5583117 B2 JP 5583117B2
Authority
JP
Japan
Prior art keywords
subject
expression
biomarker
biomarkers
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011508777A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011523549A5 (enExample
JP2011523549A (ja
Inventor
ミン‐サウンド ツァオ
フランセス エー． シェパード
イーゴリ ジュリシカ
サンディー ディー． デール
チャン‐キ ズー
ダン ストランプ
レスリー セイモア
キュー ディン
Original Assignee
ユニバーシティー ヘルス ネットワーク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティー ヘルス ネットワーク filed Critical ユニバーシティー ヘルス ネットワーク
Publication of JP2011523549A publication Critical patent/JP2011523549A/ja
Publication of JP2011523549A5 publication Critical patent/JP2011523549A5/ja
Application granted granted Critical
Publication of JP5583117B2 publication Critical patent/JP5583117B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/30—Unsupervised data analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Public Health (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Data Mining & Analysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Databases & Information Systems (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Artificial Intelligence (AREA)
  • Hematology (AREA)
  • Bioethics (AREA)
  • Evolutionary Computation (AREA)
  • Software Systems (AREA)
  • Urology & Nephrology (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • General Engineering & Computer Science (AREA)
JP2011508777A 2008-05-14 2009-05-14 非小細胞肺癌およびアジュバント化学療法に関する予後診断的および予測的な遺伝子シグネチャー Expired - Fee Related JP5583117B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7172808P 2008-05-14 2008-05-14
US61/071,728 2008-05-14
PCT/CA2009/000650 WO2009137921A1 (en) 2008-05-14 2009-05-14 Prognostic and predictive gene signature for non-small cell lung cancer and adjuvant chemotherapy

Publications (3)

Publication Number Publication Date
JP2011523549A JP2011523549A (ja) 2011-08-18
JP2011523549A5 JP2011523549A5 (enExample) 2012-07-05
JP5583117B2 true JP5583117B2 (ja) 2014-09-03

Family

ID=41318311

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011508777A Expired - Fee Related JP5583117B2 (ja) 2008-05-14 2009-05-14 非小細胞肺癌およびアジュバント化学療法に関する予後診断的および予測的な遺伝子シグネチャー

Country Status (6)

Country Link
US (3) US8211643B2 (enExample)
EP (1) EP2288741B1 (enExample)
JP (1) JP5583117B2 (enExample)
AU (1) AU2009246009A1 (enExample)
CA (1) CA2761571A1 (enExample)
WO (1) WO2009137921A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100184063A1 (en) * 2008-05-14 2010-07-22 Ming-Sound Tsao Prognostic and predictive gene signature for non-small cell lung cancer and adjuvant chemotherapy
AU2009246009A1 (en) 2008-05-14 2009-11-19 University Health Network Prognostic and predictive gene signature for non-small cell lung cancer and adjuvant chemotherapy
US20110238322A1 (en) * 2008-11-03 2011-09-29 Precision Therapeutics, Inc. Methods of simulating chemotherapy for a patient
CN101705306B (zh) * 2009-12-01 2012-07-11 华中农业大学 应用as-pcr检测牛尿苷酸合酶缺乏症的方法
US9607202B2 (en) 2009-12-17 2017-03-28 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of generating trophectoderm and neurectoderm from human embryonic stem cells
WO2011160118A2 (en) * 2010-06-18 2011-12-22 Med Biogene Inc. Prognostic and predictive gene signature for non-small cell lung cancer and adjuvant chemotherapy
US9200325B2 (en) * 2011-04-01 2015-12-01 Indiana University Research And Technology Corporation Diagnostic methods and kit for detecting cancer
PT2714926E (pt) * 2011-05-25 2015-11-03 Novartis Ag Biomarcadores para o cancro do pulmão
EP2739751A1 (en) * 2011-08-03 2014-06-11 Signal Pharmaceuticals, LLC Identification of gene expression profile as a predictive biomarker for lkb1 status
EP3563864A1 (en) 2013-01-18 2019-11-06 Kline, Ellis Selective glycosidase regimen for immune programming and treatment of cancer
CN104981697B (zh) 2013-02-11 2017-08-04 英丘伦有限责任公司 促染色质转录复合物(fact)在癌症中的用途
EP2971156B1 (en) 2013-03-15 2020-07-15 Myriad Genetics, Inc. Genes and gene signatures for diagnosis and treatment of melanoma
KR101830700B1 (ko) * 2013-11-11 2018-02-21 주식회사 파나진 클램핑 프로브 및 검출 프로브를 이용한 다중 표적핵산 검출방법
WO2015154064A2 (en) 2014-04-04 2015-10-08 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
WO2016003810A1 (en) 2014-07-02 2016-01-07 Myriad Genetics, Inc. Genes and gene signatures for diagnosis and treatment of melanoma
JP7016466B2 (ja) * 2014-09-24 2022-02-07 国立研究開発法人国立がん研究センター 扁平上皮がんに対する化学放射線療法の有効性を評価するための方法
WO2016050623A1 (en) * 2014-09-29 2016-04-07 Institut Gustave Roussy Prognosis markers in lung cancer
CN106755309A (zh) * 2016-11-18 2017-05-31 北京致成生物医学科技有限公司 分子标记物在制备胰腺癌预后评估产品中的应用
JP7106810B2 (ja) * 2018-04-19 2022-07-27 学校法人 埼玉医科大学 新規肺がんマーカー
CN108949997A (zh) * 2018-08-24 2018-12-07 南京求臻基因科技有限公司 一种肺癌检测标志物及诊断试剂盒
CN109859801B (zh) * 2019-02-14 2023-09-19 辽宁省肿瘤医院 一种含有七个基因作为生物标志物预测肺鳞癌预后的模型及建立方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US7332590B2 (en) 2001-08-16 2008-02-19 The United States Of America As Represented By The Department Of Health And Human Services Molecular characteristics of non-small cell lung cancer
US20040241725A1 (en) * 2003-03-25 2004-12-02 Wenming Xiao Lung cancer detection
US20100184063A1 (en) * 2008-05-14 2010-07-22 Ming-Sound Tsao Prognostic and predictive gene signature for non-small cell lung cancer and adjuvant chemotherapy
AU2009246009A1 (en) 2008-05-14 2009-11-19 University Health Network Prognostic and predictive gene signature for non-small cell lung cancer and adjuvant chemotherapy

Also Published As

Publication number Publication date
EP2288741A4 (en) 2011-08-24
JP2011523549A (ja) 2011-08-18
AU2009246009A1 (en) 2009-11-19
US8211643B2 (en) 2012-07-03
WO2009137921A1 (en) 2009-11-19
US20120323594A1 (en) 2012-12-20
EP2288741A1 (en) 2011-03-02
US20090291448A1 (en) 2009-11-26
US20160024596A1 (en) 2016-01-28
EP2288741B1 (en) 2015-01-28
CA2761571A1 (en) 2009-11-19

Similar Documents

Publication Publication Date Title
JP5583117B2 (ja) 非小細胞肺癌およびアジュバント化学療法に関する予後診断的および予測的な遺伝子シグネチャー
JP6824923B2 (ja) 胃腸癌での増殖の徴候及び予後
US20160032407A1 (en) Prognostic and predictive gene signature for non-small cell lung cancer and adjuvant chemotherapy
US20120258878A1 (en) Prognostic gene signatures for non-small cell lung cancer
JP6404304B2 (ja) メラノーマ癌の予後予測
US9631239B2 (en) Method of classifying a breast cancer instrinsic subtype
ES2525382T3 (es) Método para la predicción de recurrencia del cáncer de mama bajo tratamiento endocrino
JP2020031642A (ja) 遺伝子発現を用いた前立腺癌の予後を定量化する方法
WO2012066451A1 (en) Prognostic and predictive gene signature for colon cancer
EP2304631A1 (en) Algorithms for outcome prediction in patients with node-positive chemotherapy-treated breast cancer
US20160053327A1 (en) Compositions and methods for prediction of clinical outcome for all stages and all cell types of non-small cell lung cancer in multiple countries
US20250137066A1 (en) Compostions and methods for diagnosing lung cancers using gene expression profiles
US20120077687A1 (en) Prognostic and predictive gene signature for non-small cell lung cancer and adjuvant chemotherapy
AU2015227398B2 (en) Method for using gene expression to determine prognosis of prostate cancer
AU2018244758B2 (en) Method and kit for diagnosing early stage pancreatic cancer
HK1145342B (en) Prognosis prediction for melanoma cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120511

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120511

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120518

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131216

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140228

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140307

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140529

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140618

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140715

R150 Certificate of patent or registration of utility model

Ref document number: 5583117

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees